Nisha Nanda, Ph.D.

Nisha Nanda serves as Chief Development Officer, Loxo Oncology at Lilly. While at Loxo, Nisha has held roles of increasing responsibility in both clinical and pre-clinical development and most recently worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo). Prior to joining Loxo, Nisha's career in drug development included roles at Onyx, ChemGenex, Portola, Millennium and Cor.

Nisha earned a BSc Hons in Biochemistry and Molecular Genetics from UNSW, Sydney, Australia and a doctorate in Biochemistry and Molecular Genetics from UNSW and the Victor Chang Cardiac Research Institute, Sydney, Australia.